Clinical Trial

Clinical Study of Combined Platelet Transfusion

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 26, 2024 (before its estimated July 29, 2025 completion). Its status may not reflect the trial's current state.
Summary
Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.
Trial Details
NCT Number NCT06613425
Lead Sponsor The General Hospital of Western Theater Command
Conditions Hematologic Diseases
Enrollment 86 participants
Start Date 2024-08-01
Primary Completion 2025-07-29 (estimated)
Study Completion 2025-10-28 (estimated)
Updated on ClinicalTrials.gov 2024-09-26